About GemPharmatech
GemPharmatech is a company based in Nanjing (China) founded in 2018.. GemPharmatech has raised $81.85 million across 2 funding rounds from investors including Morgan Stanley, Sinopharm Group and Hillhouse. The company has 10 employees as of December 31, 2022. GemPharmatech operates in a competitive market with competitors including Biocytogen, Applied StemCell, Interius Biotherapeutics, Nagi Bioscience and Business Catalyst, among others.
- Headquarter Nanjing, China
- Employees 10 as on 31 Dec, 2022
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Gempharmatech Co., Ltd. Class A
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$81.85 M (USD)
in 2 rounds
-
Latest Funding Round
$58.49 M (USD), Series B
Sep 11, 2020
-
Investors
Morgan Stanley
& 6 more
-
Employee Count
10
as on Dec 31, 2022
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of GemPharmatech
GemPharmatech is a publicly listed company on the SSE with ticker symbol 688046 in China, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Unlock access to complete
Unlock access to complete
Funding Insights of GemPharmatech
GemPharmatech has successfully raised a total of $81.85M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $58.49 million completed in September 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 2
- Last Round Series B — $58.5M
-
First Round
First Round
(02 Jul 2019)
- Investors Count 7
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep, 2020 | Amount | Series B - GemPharmatech | Valuation | Hillhouse , Yunfeng Capital |
|
| Jul, 2019 | Amount | Series A - GemPharmatech | Valuation | CDH , Sinopharm Group |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in GemPharmatech
GemPharmatech has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include Morgan Stanley, Sinopharm Group and Hillhouse. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Global private equity investments are managed with long-term focus.
|
Founded Year | Domain | Location | |
|
Private equity investments are managed by Yunfeng Capital in China.
|
Founded Year | Domain | Location | |
|
TF Capital is engaged in biotech investment and strategic support.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by GemPharmatech
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - GemPharmatech
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Gempharmatech Comparisons
Competitors of GemPharmatech
GemPharmatech operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Biocytogen, Applied StemCell, Interius Biotherapeutics, Nagi Bioscience and Business Catalyst, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Integrated solutions for next-generation antibody drug development are provided.
|
|
| domain | founded_year | HQ Location |
Provider of animal and cell line models as tools for drug discovery and diagnostics
|
|
| domain | founded_year | HQ Location |
Developer of gene therapies for treating multiple diseases
|
|
| domain | founded_year | HQ Location |
Developer of a organism on a chip based technology
|
|
| domain | founded_year | HQ Location |
In-vivo mouse models are developed for biomedical R&D applications.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Gempharmatech
Frequently Asked Questions about GemPharmatech
When was GemPharmatech founded?
GemPharmatech was founded in 2018 and raised its 1st funding round 1 year after it was founded.
Where is GemPharmatech located?
GemPharmatech is headquartered in Nanjing, China. It is registered at Nanjing, Jiangsu, China.
Is GemPharmatech a funded company?
GemPharmatech is a funded company, having raised a total of $81.85M across 2 funding rounds to date. The company's 1st funding round was a Series A of $23.36M, raised on Jul 02, 2019.
How many employees does GemPharmatech have?
As of Dec 31, 2022, the latest employee count at GemPharmatech is 10.
What does GemPharmatech do?
GemPharmatech was founded in 2018 and is located in Nanjing, China. Operations focus on the biotechnology sector, where humanized animal models are developed for drug and disease metabolism studies. Services include functional analysis, evaluation of transgenic mice, ES gene editing, and other model types. Additional technical support encompasses cell-line services and biological sample refrigeration, aiding research applications in pharmacology and related fields.
Who are the top competitors of GemPharmatech?
GemPharmatech's top competitors include Biocytogen, Applied StemCell and Interius Biotherapeutics.
Is GemPharmatech publicly traded?
Yes, GemPharmatech is publicly traded on SSE under the ticker symbol 688046.
Who are GemPharmatech's investors?
GemPharmatech has 7 investors. Key investors include Morgan Stanley, Sinopharm Group, Hillhouse, Yunfeng Capital, and Sequoia Capital.
What is GemPharmatech's ticker symbol?
The ticker symbol of GemPharmatech is 688046 on SSE.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.